The impact of survivorship bias in glioblastoma research

Despite advances in the therapy of Central Nervous System (CNS) malignancies, treatment of glioblastoma (GB) poses significant challenges due to GB resistance and high recurrence rates following post-operative radio-chemotherapy. The majority of prognostic and predictive GB biomarkers are currently...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Critical reviews in oncology/hematology 2023-08, Vol.188, p.104065-104065, Article 104065
Hauptverfasser:	Pasqualetti, Francesco, Barberis, Alessandro, Zanotti, Sofia, Montemurro, Nicola, De Salvo, Gian Luca, Soffietti, Riccardo, Mazzanti, Chiara Maria, Ius, Tamara, Caffo, Maria, Paiar, Fabiola, Bocci, Guido, Lombardi, Giuseppe, Harris, Adrian L., Buffa, Francesca M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Biomarkers Biomarkers, Tumor - metabolism Brain Neoplasms - diagnosis Brain Neoplasms - genetics Brain Neoplasms - therapy Dacarbazine DNA Methylation DNA Repair Enzymes - genetics DNA Repair Enzymes - metabolism DNA Repair Enzymes - therapeutic use Glioblastoma Glioblastoma - drug therapy Humans Liquid biopsy Methodology O6-methylguanine-DNA methyltransferase (MGMT) methylation Prognosis Selection bias Survivorship Temozolomide - therapeutic use Translational research
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!